2022-2023季二价mRNA新冠疫苗与流感疫苗接种后缺血性卒中风险:多站点自身对照病例系列研究
美国疫苗安全数据链(VSD)八站点在2022年9月1日至2023年3月31日对≥12岁人群开展事件依赖自身对照病例系列研究,共识别6510例首次缺血性卒中。结果显示,接种二价mRNA新冠疫苗、流感疫苗或同日联合接种后1-21天及1-42天风险区间均未见缺血性卒中风险显著升高,亚组及次要结局结果一致。
要点
- 二价mRNA新冠疫苗接种后1-21天首次缺血性卒中相对发病率为0.94(95%CI 0.63-1.41)。
- 流感疫苗接种后1-21天首次缺血性卒中相对发病率为0.95(95%CI 0.82-1.10)。
- 同日联合接种后1-21天首次缺血性卒中相对发病率为1.15(95%CI 0.88-1.49)。
核心结论
- 多站点自身对照病例系列研究未发现接种二价mRNA新冠疫苗、流感疫苗或同日联合接种后缺血性卒中风险增加。
研究设计与样本
- 采用事件依赖自身对照病例系列设计,基于美国疫苗安全数据链八个站点,纳入2022年9月1日至2023年3月31日期间≥12岁人群。
- 主要结局为首次缺血性卒中,次要结局为一年内首次缺血性卒中,探索性结局为缺血性事件,通过住院和急诊ICD-10-CM编码识别。
- 分析分别针对Pfizer-BioNTech和Moderna二价疫苗,估计1-21天和1-42天风险区间的相对发病率及95%置信区间,以风险区间外的人时作为对照期。
- 按年龄组(12-64岁、≥65岁)和 documented SARS-CoV-2感染史进行亚组分析。
主要发现
- Pfizer-BioNTech二价新冠疫苗接种后1-21天首次缺血性卒中相对发病率为0.94(95%CI 0.63-1.41),流感疫苗接种后为0.95(95%CI 0.82-1.10),同日联合接种后为1.15(95%CI 0.88-1.49)。
- 1-42天风险区间结果与1-21天相似。
- Moderna疫苗及所有亚组、次要结局和探索性结局均观察到一致的无效结果。
临床怎么用
- 研究结果支持在2022-2023季接种二价mRNA新冠疫苗和流感疫苗时无需因缺血性卒中风险担忧而改变接种建议。
- 对于有SARS-CoV-2感染史或不同年龄组人群,接种后缺血性卒中风险未见显著增加,可据此进行个体化沟通。
- 持续开展疫苗安全监测对验证罕见不良事件信号仍然重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Vaccine Safety Datalink (VSD) detected a statistical signal for ischemic events (ischemic stroke or transient ischemic attack) following bivalent mRNA COVID-19 vaccination through prospective surveillance during 2022-2023. Although multiple studies from other surveillance systems and countries reported no increased risk, important methodological limitations remained. This U.S. study addressed those limitations by evaluating the ischemic stroke risk following bivalent mRNA COVID-19 vaccination, influenza vaccination, and their same-day coadministration using an event-dependent self-controlled case series (SCCS) design. METHODS: Study outcomes included first-ever ischemic stroke (primary outcome), first-in-1-year ischemic stroke (secondary outcome), and ischemic events (exploratory outcomes), identified using ICD-10-CM codes in inpatient and emergency department settings during September 1, 2022-March 31, 2023, among individuals aged ≥12 years across eight VSD sites. Analyses were conducted separately for Pfizer-BioNTech and Moderna bivalent vaccines, with relative incidences (RI) and 95% confidence intervals (CI) estimated for 1-21-day and 1-42-day risk intervals, using person-time outside these intervals as the control period. Subgroup analyses were performed by age group (12-64, ≥65 years) and history of documented SARS-CoV-2 infection. RESULTS: A total of 6510 first-ever ischemic strokes were identified among more than 6.8 million participants. Among recipients of Pfizer-BioNTech bivalent COVID-19 and influenza vaccines, no statistically significant increased risk of first-ever ischemic stroke was observed following bivalent COVID-19 vaccination (RI = 0.94; 95% CI: 0.63-1.41), influenza vaccination (RI = 0.95; 95% CI: 0.82-1.10), or same-day coadministration (RI = 1.15; 95% CI: 0.88-1.49) within 1-21-day risk intervals; findings were similar for 1-42-day intervals. Comparable null results were observed for Moderna vaccine and across all subgroups, secondary, and exploratory outcomes. CONCLUSION: No increased risk of ischemic stroke was found following bivalent mRNA COVID-19 vaccination, influenza vaccination, or their coadministration in this multi-site SCCS study. These findings are consistent with previous studies and underscore the importance of continued vaccine safety monitoring.
引用
- Xu S, Sy LS, Hong V, et al. Ischemic stroke after bivalent mRNA COVID-19 vaccination and influenza vaccination during the 2022-2023 season: a multi-site self-controlled case series study. Vaccine. 2026. PMID: 42914658. doi:10.1016/j.vaccine.2026.129263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。